Search Site

Trends banner

‘Wadeem’ sold out for $1.49bn

This is the highest Abu Dhabi real-estate release to date.

Tesla Q2 sales down 13.5%

Shares rally after the disclosure, better than some forecasts.

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

Bristol Myers to buy Mirati

The statement said that both companies' boards of directors had approved the agreement.
  • The companies said in a joint statement that Bristol Myers Squibb will pay $58 per share in cash "for a total equity value of $4.8 billion"
  • The statement added that with the acquisition Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio

Washington, United States–US pharmaceutical company Bristol Myers Squibb announced a $4.8 billion deal on Sunday to acquire cancer drugmaker Mirati Therapeutics.

Bristol Myers Squibb will pay $58 per share in cash “for a total equity value of $4.8 billion,” the companies said in a joint statement.

In addition, a guaranteed value certificate (GVC) could provide Mirati shareholders with a potential additional $12.00 per share, or up to an additional $1 billion in total.

The statement said that both companies’ boards of directors had approved the agreement.

“Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio,” the statement said.

It said KRAZATI targets a specific type of mutation that makes up 14 percent of non-small cell lung cancer diagnoses.

“With multiple targeted oncology assets including KRAZATI, Mirati is another important step forward in our efforts to grow our diversified oncology portfolio and further strengthen Bristol Myers Squibb’s pipeline for the latter half of the decade and beyond,” said Chris Boerner, the company’s executive vice president and incoming CEO.